ANIP 8-K: SEC filing
ANI Pharmaceuticals
Filed with the SEC on · accession 0001023024-26-000077
ANIP filed a 8-K (current report) with the SEC on Nov 5, 2026. ANI Pharmaceuticals announced its third quarter 2026 financial results and provided a presentation regarding its proposed acquisition of Egetis Therapeutics.
Summary of the filing
ANI Pharmaceuticals announced its third quarter 2026 financial results and provided a presentation regarding its proposed acquisition of Egetis Therapeutics. The filing is an 8-K furnishing earnings results and an investor presentation.
Key details
✦ Ask GOAX AI about this filing — what it means for ANIP, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for ANIP?
Click hereFrequently asked questions
What did ANIP file with the SEC on Nov 5, 2026?
ANIP filed a 8-K (SEC filing). ANI Pharmaceuticals announced its third quarter 2026 financial results and provided a presentation regarding its proposed acquisition of Egetis Therapeutics. The filing is an 8-K furnishing earnings results and an investor presentation.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other ANIP SEC filings
Get alerts when ANIP files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days